Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cardiol Therapeutics (CRDL) Net Income towards Common Stockholders (2020 - 2026)

Cardiol Therapeutics filings provide 2 years of Net Income towards Common Stockholders readings, the most recent being -$6.3 million for Q4 2022.

  • On a quarterly basis, Net Income towards Common Stockholders changed N/A to -$6.3 million in Q4 2022 year-over-year; TTM through Dec 2022 was -$31.4 million, a 53.84% decrease, with the full-year FY2025 number at -$24.0 million, up 15.78% from a year prior.
  • Net Income towards Common Stockholders hit -$6.3 million in Q4 2022 for Cardiol Therapeutics, up from -$10.1 million in the prior quarter.
  • In the past five years, Net Income towards Common Stockholders ranged from a high of -$5.2 million in Q2 2021 to a low of -$10.1 million in Q3 2022.